|
| 37098956 | Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization. | | 2023 |
| 36347257 | Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. | Cell Host Microbe | 2023 |
| 37766115 | Enhancing Anti-SARS-CoV-2 Neutralizing Immunity by Genetic Delivery of Enveloped Virus-like Particles Displaying SARS-CoV-2 Spikes. | Vaccines (Basel) | 2023 |
| 37756379 | A MERS-CoV antibody neutralizes a pre-emerging group 2c bat coronavirus. | Sci Transl Med | 2023 |
| 37738240 | Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus. | PLoS Pathog | 2023 |
| 37737588 | Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope. | | 2023 |
| 37989731 | Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site. | | 2023 |
| 37553406 | Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery. | NPJ Vaccines | 2023 |
| 37345226 | Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain. | | 2023 |
| 37075126 | An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. | | 2023 |
| 37196074 | EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. | Sci Adv | 2023 |
| 37321165 | Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. | Cell Host Microbe | 2023 |
| 37001964 | Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial. | | 2023 |
| 37300931 | Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. | EBioMedicine | 2023 |
| 36729903 | Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency. | MAbs | 2023 |
| 36848985 | Rhesus macaque Bcl-6/Bcl-xL B cell immortalization: Discovery of HIV-1 neutralizing antibodies from lymph node. | | 2023 |
| 37544326 | Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial. | Lancet Infect Dis | 2023 |
| 37349337 | Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections. | Nat Commun | 2023 |
| 35324257 | Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. | Science | 2022 |
| 36306784 | Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition. | Immunity | 2022 |
| 35841885 | Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. | Structure | 2022 |
| 35709309 | Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4. | PLoS Pathogens | 2022 |
| 35447072 | mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. | Cell | 2022 |
| 36356572 | Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses. | Immunity | 2022 |
| 36157588 | Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responses. | iScience | 2022 |
| 35441178 | Broadly neutralizing antibodies target the coronavirus fusion peptide. | bioRxiv | 2022 |
| 36284200 | Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life. | Scientific Reports | 2022 |
| 35568049 | Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial. | Lancet Infectious Diseases, The | 2022 |
| 35568025 | LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. | Cell Rep | 2022 |
| 35378757 | Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. | bioRxiv | 2022 |
| 35731888 | Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. | Science Translational Medicine | 2022 |
| 35551291 | Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. | Nature Medicine | 2022 |
| 35609088 | Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. | PLoS ONE | 2022 |
| 35547849 | Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine - An Interim Analysis. | | 2022 |
| 35921449 | Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria. | New England Journal of Medicine | 2022 |
| 35783486 | Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. | eClinicalMedicine | 2022 |
| 36423012 | Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1. | Vaccines | 2022 |
| 36517467 | Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. | Nat Commun | 2022 |
| 36582240 | Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings. | Front Immunol | 2022 |
| 34213402 | Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. | Hum Vaccin Immunother | 2022 |
| 33972947 | LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. | bioRxiv | 2022 |
| 35319830 | Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2. | Advanced Science | 2022 |
| 34986348 | Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. | Cell Rep | 2022 |
| 34923559 | Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials. | J Acquir Immune Defic Syndr | 2022 |
| 34921774 | Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. | Cell | 2022 |
| 35283191 | Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2. | Journal of Biological Chemistry | 2022 |
| 35264559 | First-in-human immunoPET imaging of HIV-1 infection using <sup>89</sup>Zr-labeled VRC01 broadly neutralizing antibody. | Nat Commun | 2022 |
| 35134995 | Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention. | Journal of Infectious Diseases | 2022 |
| 35115707 | A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. | Nature Medicine | 2022 |
| 35081298 | SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. | N Engl J Med | 2022 |